Odyssey Therapeutics' IPO terms announcement on May 4, 2026—targeting up to $238 million in proceeds from 13.2 million shares priced $16–$18, implying an $810 million fully diluted valuation—has sharpened trader focus on debut trading under ticker ODTX, expected imminently. Polymarket's closely matched implied probabilities across market cap buckets reflect biotech sector volatility, with no clear consensus on first-day pops amid cooling IPO fervor; the <$0.8 billion outcome edges at 49.5% due to prior 2025 withdrawal amid tough listings. Key drivers include April 2026 Phase 2a proof-of-concept for lead RIPK2 inhibitor OD-001 in ulcerative colitis, differentiating via first-in-class scaffolding mechanism addressing IBD non-responders, bolstered by $213 million Series D. Phase 2b readouts in H2 2026 loom as pivotal catalysts.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado$0.8B–$1.1B 41%
$1.1B–$1.4B 20%
$1.4 mil millones+ 16%
< $0.8B 8%
NUEVO
NUEVO
8 may 2026
< $0.8B
8%
$0.8B–$1.1B
41%
$1.1B–$1.4B
20%
$1.4 mil millones+
16%
No IPO before July 2026
3%
$0.8B–$1.1B 41%
$1.1B–$1.4B 20%
$1.4 mil millones+ 16%
< $0.8B 8%
NUEVO
NUEVO
8 may 2026
< $0.8B
$43 Vol.
8%
$0.8B–$1.1B
$186 Vol.
41%
$1.1B–$1.4B
$35 Vol.
20%
$1.4 mil millones+
$56 Vol.
16%
No IPO before July 2026
$58 Vol.
3%
This market will resolve based on Odyssey Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Odyssey Therapeutics' IPO terms announcement on May 4, 2026—targeting up to $238 million in proceeds from 13.2 million shares priced $16–$18, implying an $810 million fully diluted valuation—has sharpened trader focus on debut trading under ticker ODTX, expected imminently. Polymarket's closely matched implied probabilities across market cap buckets reflect biotech sector volatility, with no clear consensus on first-day pops amid cooling IPO fervor; the <$0.8 billion outcome edges at 49.5% due to prior 2025 withdrawal amid tough listings. Key drivers include April 2026 Phase 2a proof-of-concept for lead RIPK2 inhibitor OD-001 in ulcerative colitis, differentiating via first-in-class scaffolding mechanism addressing IBD non-responders, bolstered by $213 million Series D. Phase 2b readouts in H2 2026 loom as pivotal catalysts.
This market will resolve based on Odyssey Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Mercado abierto: May 5, 2026, 7:07 PM ET
Volumen
$373Fecha de finalización
8 may 2026Mercado abierto
May 5, 2026, 7:07 PM ETResolver
0x69c47De9D...This market will resolve based on Odyssey Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Odyssey Therapeutics' IPO terms announcement on May 4, 2026—targeting up to $238 million in proceeds from 13.2 million shares priced $16–$18, implying an $810 million fully diluted valuation—has sharpened trader focus on debut trading under ticker ODTX, expected imminently. Polymarket's closely matched implied probabilities across market cap buckets reflect biotech sector volatility, with no clear consensus on first-day pops amid cooling IPO fervor; the <$0.8 billion outcome edges at 49.5% due to prior 2025 withdrawal amid tough listings. Key drivers include April 2026 Phase 2a proof-of-concept for lead RIPK2 inhibitor OD-001 in ulcerative colitis, differentiating via first-in-class scaffolding mechanism addressing IBD non-responders, bolstered by $213 million Series D. Phase 2b readouts in H2 2026 loom as pivotal catalysts.
This market will resolve based on Odyssey Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$373Fecha de finalización
8 may 2026Mercado abierto
May 5, 2026, 7:07 PM ETResolver
0x69c47De9D...Odyssey Therapeutics' IPO terms announcement on May 4, 2026—targeting up to $238 million in proceeds from 13.2 million shares priced $16–$18, implying an $810 million fully diluted valuation—has sharpened trader focus on debut trading under ticker ODTX, expected imminently. Polymarket's closely matched implied probabilities across market cap buckets reflect biotech sector volatility, with no clear consensus on first-day pops amid cooling IPO fervor; the <$0.8 billion outcome edges at 49.5% due to prior 2025 withdrawal amid tough listings. Key drivers include April 2026 Phase 2a proof-of-concept for lead RIPK2 inhibitor OD-001 in ulcerative colitis, differentiating via first-in-class scaffolding mechanism addressing IBD non-responders, bolstered by $213 million Series D. Phase 2b readouts in H2 2026 loom as pivotal catalysts.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes